Optimizing SN22 Nanoparticles to Treat Children with High-Risk Neuroblastomas
Project Title: Optimizing SN22 Nanoparticles to Treat Children with High-Risk
Neuroblastomas
Researcher: Garrett Brodeur, MD
Institution: Children’s Hospital of Philadelphia (CHOP)
Study Type: Pre-Clinical
Project Summary
Nanotechnology is a rapidly emerging field with the potential to revolutionize drug
delivery, and is expected to affect every major arena of drug development in the coming
years.
Advances in this area have allowed some nanomedicines in the market to achieve
favorable pharmacokinetic properties, reduce toxicity, and improve patient outcomes. However, there has been very limited application of nanoparticle drugs in children with cancer.
This research study developed a new therapy for children with neuroblastoma and other
solid tumors and has the potential to impact frontline regimens for children in need of more effective and less toxic therapies.
Impact
This translational research developed a shelf-stable formulation to be introduced
into clinical trials for children. Significantly, this same nanoparticle formulation could be used to treat, essentially, any recurrent/refractory solid tumor.